{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:23:23Z","timestamp":1790792603038,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.therap.2018.11.015","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T14:29:23Z","timestamp":1549549763000},"page":"187-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Methods in pharmacoepidemiology"],"prefix":"10.1016","volume":"74","author":[{"given":"Agn\u00e8s","family":"Sommet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2018.11.015_bib0285","article-title":"What is pharmacoepidemiology? Definition, methods, interest and clinical applications","author":"Montastruc","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.11.015_bib0290","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00185868.1965.9953819","article-title":"A medical review of precribing","volume":"43","author":"Muller","year":"1965","journal-title":"Hosp Top"},{"key":"10.1016\/j.therap.2018.11.015_bib0295","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2307\/3348898","article-title":"Primary medical care. 3. Prescribing in three Englis towns","volume":"43","author":"Lee","year":"1965","journal-title":"Milbank Mem Fund Q"},{"issue":"2","key":"10.1016\/j.therap.2018.11.015_bib0300","first-page":"142","article-title":"Outpatient drug prescribing related to clinic utilization in four New York City hospitals","volume":"3","author":"Muller","year":"1968","journal-title":"Health Serv Res"},{"issue":"3","key":"10.1016\/j.therap.2018.11.015_bib0305","first-page":"170","article-title":"Personal factors as a cause of differences in prescribing by general practitioners","volume":"22","author":"Joyce","year":"1968","journal-title":"Br J Prev Soc Med"},{"issue":"6","key":"10.1016\/j.therap.2018.11.015_bib0310","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S0002-9378(99)70411-4","article-title":"Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. 1971","volume":"181","author":"Herbst","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.therap.2018.11.015_bib0315","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2307\/2530744","article-title":"Biased selection of controls for case-control analyses of cohort studies","volume":"40","author":"Lubin","year":"1984","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.therap.2018.11.015_bib0320","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/aje\/kwn135","article-title":"Immeasurable time bias in observational studies of drug effects on mortality","volume":"168","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.therap.2018.11.015_bib0325","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2515\/therapie\/2014207","article-title":"Immortal time bias in pharmacoepidemiological studies: definition, solutions and examples","volume":"70","author":"Faillie","year":"2015","journal-title":"Therapie"},{"issue":"19","key":"10.1016\/j.therap.2018.11.015_bib0330","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.therap.2018.11.015_bib0335","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events","volume":"133","author":"Maclure","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"20","key":"10.1016\/j.therap.2018.11.015_bib0340","first-page":"817","article-title":"Claude Bernard's philosophy of medical science","volume":"65","author":"Sloan","year":"1984","journal-title":"S Afr Med J"},{"issue":"2","key":"10.1016\/j.therap.2018.11.015_bib0345","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jac\/dkh342","article-title":"No significant decrease in antibiotic use from 1992 to 2000, in the French community","volume":"54","author":"Sommet","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.therap.2018.11.015_bib0350","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.therap.2017.03.002","article-title":"Outpatient consumption of antibiotics with a bacterial resistance risk in 2014 in France","volume":"72","author":"Casaurancq","year":"2017","journal-title":"Therapie"},{"issue":"1","key":"10.1016\/j.therap.2018.11.015_bib0355","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01953.x","article-title":"Differences between clinical trials and postmarketing use","volume":"57","author":"Martin","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.therap.2018.11.015_bib0360","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJM198904133201510","article-title":"When a uniquely effective drug is teratogenic. The case of isotretinoin","volume":"320","author":"Stern","year":"1989","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.therap.2018.11.015_bib0365","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.therap.2018.11.015_bib0370","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0002-9343(90)90182-D","article-title":"Developing improved observational methods for evaluating therapeutic effectiveness","volume":"89","author":"Horwitz","year":"1990","journal-title":"Am J Med"},{"issue":"14","key":"10.1016\/j.therap.2018.11.015_bib0375","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1001\/jama.1989.03420140089033","article-title":"Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure","volume":"261","author":"Psaty","year":"1989","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.therap.2018.11.015_bib0380","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.therap.2016.09.020","article-title":"False-positive results in pharmacoepidemiology and pharmacovigilance","volume":"72","author":"Bezin","year":"2017","journal-title":"Therapie"},{"issue":"9","key":"10.1016\/j.therap.2018.11.015_bib0385","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jamda.2017.04.014","article-title":"Mortality and antipsychotic drug use in elderly patients with Parkinson disease in nursing homes","volume":"18","author":"Thu Trang","year":"2017","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"10.1016\/j.therap.2018.11.015_bib0390","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","article-title":"French health insurance databases: what interest for medical research?","volume":"36","author":"Moulis","year":"2015","journal-title":"Rev Med Interne"},{"issue":"4","key":"10.1016\/j.therap.2018.11.015_bib0395","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/pds.1549","article-title":"Using prescription registries to define continuous drug use: how to fill gaps between prescriptions","volume":"17","author":"Nielsen","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.therap.2018.11.015_bib0400","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00315097","article-title":"Measurement of drug use in a defined population. Evaluation of the defined daily dose (DDD) methodology","volume":"39","author":"Wessling","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.11.015_bib0405","series-title":"Enqu\u00eate Sant\u00e9 Insee","year":"2018"},{"issue":"3","key":"10.1016\/j.therap.2018.11.015_bib0410","doi-asserted-by":"crossref","first-page":"e34187","DOI":"10.1371\/journal.pone.0034187","article-title":"Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non-steroidal anti-inflammatory drugs: a cohort study","volume":"7","author":"Fournier","year":"2012","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.therap.2018.11.015_bib0415","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1684\/bdc.2013.1738","article-title":"Observance des m\u00e9dicaments anticanc\u00e9reux","volume":"100","author":"Despas","year":"2013","journal-title":"Bull Cancer"},{"issue":"7","key":"10.1016\/j.therap.2018.11.015_bib0420","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.4000","article-title":"How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women?","volume":"25","author":"Hurault-Delarue","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.therap.2018.11.015_bib0425","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.therap.2018.11.015_bib0430","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1524-4733.2009.00543.x","article-title":"Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia","volume":"12","author":"Karve","year":"2009","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.therap.2018.11.015_bib0435","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/fcp.12363","article-title":"Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients","volume":"32","author":"Rwagitinywa","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.therap.2018.11.015_bib0440","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/pds.892","article-title":"Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database","volume":"13","author":"Pradel","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.therap.2018.11.015_bib0445","first-page":"89","article-title":"Doctor shopping reveals geographical variations in opioid abuse","volume":"16","author":"Nordmann","year":"2013","journal-title":"Pain Physician"},{"issue":"2","key":"10.1016\/j.therap.2018.11.015_bib0450","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1472-8206.2010.00906.x","article-title":"Assessment of abuse of tianeptine from a reimbursement database using \u201cdoctor-shopping\u201d as an indicator","volume":"26","author":"Rouby","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2018.11.015_bib0455","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0376-8716(01)00161-2","article-title":"Buprenorphine prescription by general practitioners in a French region","volume":"65","author":"Thirion","year":"2002","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.therap.2018.11.015_bib0460","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00002018-200730030-00007","article-title":"Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France","volume":"30","author":"Boeuf","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2018.11.015_bib0465","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.drugalcdep.2018.01.036","article-title":"Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries","volume":"187","author":"Pont\u00e9","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.therap.2018.11.015_bib0470","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/11531570-000000000-00000","article-title":"Assessment of abuse potential of benzodiazepines from a prescription database using \u201cdoctor shopping\u201d as an indicator","volume":"24","author":"Pradel","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.therap.2018.11.015_bib0475","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2515\/therapie\/2015012","article-title":"Example of an investigation of an \u201cemergent\u201d phenomenon in addiction vigilance: the case of methylphenidate","volume":"70","author":"Micallef","year":"2015","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.therap.2018.11.015_bib0480","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.juro.2016.03.181","article-title":"Narcotic use and postoperative doctor shopping by patients with nephrolithiasis requiring operative intervention: implications for patient safety","volume":"196","author":"Kappa","year":"2016","journal-title":"J Urol"},{"issue":"22","key":"10.1016\/j.therap.2018.11.015_bib0485","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.2008.802","article-title":"Patterns of abuse among unintentional pharmaceutical overdose fatalities","volume":"300","author":"Hall","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.therap.2018.11.015_bib0490","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jamainternmed.2013.12711","article-title":"High-risk use by patients prescribed opioids for pain and its role in overdose deaths","volume":"174","author":"Gwira Baumblatt","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.therap.2018.11.015_bib0495","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/fcp.12024","article-title":"OPPIDUM surveillance program: 20years of information on drug abuse in France","volume":"27","author":"Frauger","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.therap.2018.11.015_bib0500","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.therap.2018.11.015_bib0505","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.therap.2018.11.015_bib0510","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00228-017-2326-z","article-title":"Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients","volume":"73","author":"Pariente","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.11.015_bib0515","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jclinepi.2016.02.011","article-title":"Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications","volume":"76","author":"Kumamaru","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.therap.2018.11.015_bib0520","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","article-title":"Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study","volume":"55","author":"Neumann","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.therap.2018.11.015_bib0525","doi-asserted-by":"crossref","first-page":"i1541","DOI":"10.1136\/bmj.i1541","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","volume":"352","author":"Tuccori","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.therap.2018.11.015_bib0530","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/pds.3724","article-title":"Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study","volume":"24","author":"Uddin","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"15\u201316","key":"10.1016\/j.therap.2018.11.015_bib0535","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.vaccine.2004.01.017","article-title":"Control without separate controls: evaluation of vaccine safety using case-only methods","volume":"22","author":"Farrington","year":"2004","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.therap.2018.11.015_bib0540","first-page":"714","article-title":"Methods to control for unmeasured confounding in pharmacoepidemiology: an overview","volume":"38","author":"Uddin","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.therap.2018.11.015_bib0545","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"4682","key":"10.1016\/j.therap.2018.11.015_bib0550","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/bmj.2.4682.739","article-title":"Smoking and carcinoma of the lung; preliminary report","volume":"2","author":"Doll","year":"1950","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.therap.2018.11.015_bib0555","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/aje\/kwg144","article-title":"Case-crossover and case-time-control designs in birth defects epidemiology","volume":"158","author":"Hern\u00e1ndez-D\u00edaz","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.therap.2018.11.015_bib0560","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10654-017-0281-8","article-title":"Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies","volume":"32","author":"Lai","year":"2017","journal-title":"Eur J Epidemiol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:52:40Z","timestamp":1758567160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595719300290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0040595719300290"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.11.015","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methods in pharmacoepidemiology","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}